DK3539974T3 - Method for modifying t cell population - Google Patents
Method for modifying t cell population Download PDFInfo
- Publication number
- DK3539974T3 DK3539974T3 DK17870242.9T DK17870242T DK3539974T3 DK 3539974 T3 DK3539974 T3 DK 3539974T3 DK 17870242 T DK17870242 T DK 17870242T DK 3539974 T3 DK3539974 T3 DK 3539974T3
- Authority
- DK
- Denmark
- Prior art keywords
- modifying
- cell population
- population
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016219099 | 2016-11-09 | ||
PCT/JP2017/040302 WO2018088439A1 (ja) | 2016-11-09 | 2017-11-08 | T細胞集団の改変方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
DK3539974T3 true DK3539974T3 (da) | 2023-06-26 |
DK3539974T5 DK3539974T5 (en) | 2024-05-27 |
Family
ID=62110690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17870242.9T DK3539974T5 (en) | 2016-11-09 | 2017-11-08 | Method for modifying t cell population |
Country Status (6)
Country | Link |
---|---|
US (1) | US10899790B2 (da) |
EP (1) | EP3539974B1 (da) |
JP (1) | JP6994201B2 (da) |
DK (1) | DK3539974T5 (da) |
ES (1) | ES2946188T3 (da) |
WO (1) | WO2018088439A1 (da) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113698447A (zh) * | 2021-09-24 | 2021-11-26 | 河北维达康生物科技有限公司 | 一种18β-甘草次酸甲酯的制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1046413A (en) | 1964-03-24 | 1966-10-26 | Biorex Laboratories Ltd | New derivatives of glycyrrhetinic acid and process for the preparation thereof |
GB0020351D0 (en) | 2000-08-17 | 2000-10-04 | Catalyst Biomedica Ltd | Treatment of hyperproliferative diseases |
US20030032078A1 (en) | 2001-01-23 | 2003-02-13 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of macular and retinal degenerations |
AU2003242305A1 (en) | 2002-06-12 | 2003-12-31 | Chugai Seiyaku Kabushiki Kaisha | Hla-a24-restricted cancer antigen peptide |
WO2005095598A1 (ja) | 2004-03-31 | 2005-10-13 | International Institute Of Cancer Immunology, Inc. | Wt1由来の癌抗原ペプチド |
DK1988163T3 (da) | 2006-02-22 | 2012-08-20 | Int Inst Cancer Immunology Inc | Hla-a*3303-begrænset wt1 peptid og farmaceutisk sammensætning omfattende det samme |
GB0604899D0 (en) | 2006-03-10 | 2006-04-19 | York Pharma Plc | Derivatives of 18-glycyrrhetinic acid |
WO2008137488A1 (en) | 2007-05-01 | 2008-11-13 | Purdue Research Foundation | Methods for controlling inflammatory and immunological diseases |
JP2010531138A (ja) | 2007-06-13 | 2010-09-24 | ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー | 制御性t細胞ならびに同製造および使用方法 |
EP2228380A1 (en) | 2009-03-13 | 2010-09-15 | onepharm Research & Development GmbH | Novel triterpene derivatives |
US20120142109A1 (en) | 2009-08-25 | 2012-06-07 | Yoshinori Katayama | Method for producing t cell population under presence of retinoic acid |
AU2011313327B2 (en) | 2010-10-05 | 2015-10-22 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
EP3075738B1 (en) * | 2013-11-25 | 2019-02-13 | Ini Corporation | Glycyrrhetinic acid derivative and use thereof |
EP3238744A4 (en) * | 2014-12-25 | 2018-09-26 | International Institute of Cancer Immunology, Inc. | Method for modifying t cell population |
-
2017
- 2017-11-08 JP JP2018550232A patent/JP6994201B2/ja active Active
- 2017-11-08 US US16/347,337 patent/US10899790B2/en active Active
- 2017-11-08 EP EP17870242.9A patent/EP3539974B1/en active Active
- 2017-11-08 DK DK17870242.9T patent/DK3539974T5/da active
- 2017-11-08 ES ES17870242T patent/ES2946188T3/es active Active
- 2017-11-08 WO PCT/JP2017/040302 patent/WO2018088439A1/ja unknown
Also Published As
Publication number | Publication date |
---|---|
EP3539974A4 (en) | 2020-05-06 |
ES2946188T3 (es) | 2023-07-13 |
JP6994201B2 (ja) | 2022-02-21 |
DK3539974T5 (en) | 2024-05-27 |
WO2018088439A1 (ja) | 2018-05-17 |
EP3539974A1 (en) | 2019-09-18 |
JPWO2018088439A1 (ja) | 2019-10-03 |
US10899790B2 (en) | 2021-01-26 |
EP3539974B1 (en) | 2023-03-29 |
US20190284228A1 (en) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180084820A (ko) | 전기화학적 기체 분리 방법 | |
DK3444334T3 (da) | Fremgangsmåde til inducering af CD8+ T-celler | |
DK3316703T3 (da) | Fremgangsmåde til forbedring af dyrs ydeevne | |
DK3198035T3 (da) | Fremgangsmåder til forudsigelse af medicinrespons | |
DK3691296T3 (da) | Høreapparatsystem og -metode | |
DK3122444T3 (da) | Fremgangsmåde til fremstilling af membraner | |
DK3006079T3 (da) | Høresystem | |
DK3254325T3 (da) | Elektrolytdannelsesfremgangsmåde | |
DK3254326T3 (da) | Elektrolytdannelsesfremgangsmåde | |
DE112018006483A5 (de) | Elektrochemisches System | |
DK3227435T3 (da) | Gammadelta-t-celleekspansionsprocedure | |
DK3265555T3 (da) | T-celle-ekspansion | |
DK3001700T3 (da) | Positioneret høresystem | |
IL266111A (en) | Methods for inducing a t-cell response | |
DK3152332T3 (da) | Fremgangsmåde til at analysere methylering | |
DK3253906T3 (da) | Elektrolyt til elektroplettering | |
DK3766582T3 (da) | Cellekultur | |
DK3384045T3 (da) | Fremgangsmåde til bestemmelse af celleklonalitet | |
HK1243960A1 (zh) | T細胞群的改變方法 | |
DK3294257T3 (da) | Gribehjælpemiddel til beholder | |
DK3748358T3 (da) | Cellebaseret fremgangsmåde til bestemmelse af virkningsgraden af defibrotid | |
DK3190875T3 (da) | Fremgangsmåder og systemer til udklækning af æg | |
DK3391047T3 (da) | T-cellereaktivitetsplatform | |
DK3664473T3 (da) | Høreapparat | |
DK3131567T3 (da) | Fremgangsmåde til fremstilling af GNRH-holdig gel |